Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multi-center, dose escalation study that is followed by a Phase 2
randomized, double-blind, placebo-controlled study of the safety and efficacy of WP1122
administered q12h ±1 hr PO in adult patients with COVID-19 who require hospitalization with
respiratory support.
The Phase 1 component will enroll COVID-19 positive patients who are symptomatic and the
Phase 2 component will enroll adults with COVID-19 who require hospitalization for
respiratory support and those patients requiring intubation with mechanical ventilation.